In situ PEGylation of recombinant hirudin on an anion exchange chromatography column
-
Add time:08/31/2019 Source:sciencedirect.com
In this study, an integrated process was developed for successive solid-phase PEGylation of recombinant hirudin variant-2 (HV2) and separation of PEGylated HV2 species on an anion exchange chromatography column (so-called in situ PEGylation). The effects of different PEG sizes, ion exchange resins and reaction conditions on in situ PEGylation were investigated. The results showed that in situ PEGylation efficiently integrates the reaction, separation and purification into a single-unit operation using the same column. In situ PEGylation could improve the selectivity of PEGylation reactions by significantly reducing the formation of multi-PEG-HV2. The pore sizes and internal surface structures of different resins had a significant impact on the yield of mono-PEG-HV2. In contrast to liquid-phase PEGylation, the yield of mono-PEG-HV2 decreased as PEG size increased during the in situ PEGylation process, indicating that in situ PEGylation is a pore diffusion-controlled process. The in vitro and in vivo anticoagulant activities of mono-PEG-HV2 derived from in situ PEGylation were higher than those from liquid-phase PEGylation, indicating that in situ PEGylation could enhance the bioactivity retention of mono-PEG-HV2. The results of this study demonstrated that in situ PEGylation can be used as an effective approach for the development of PEGylated protein drugs.
We also recommend Trading Suppliers and Manufacturers of hirudin HV2 (cas 114265-28-0). Pls Click Website Link as below: cas 114265-28-0 suppliers
Prev:Effects of linear and branched polyethylene glycol on PEGylation of recombinant hirudin: Reaction kinetics and in vitro and in vivo bioactivities
Next:Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite in human serum) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular ArticleExpression, Purification and Characterization of Multigram Amounts of a Recombinant Hybrid HV1-HV2 Hirudin Variant Expressed in Saccharomyces cerevisiae09/04/2019
- Two-step ion-exchange chromatographic purification of recombinant hirudin-II and its C-terminal-truncated derivatives expressed in Pichia pastoris09/03/2019
- PEGylation of recombinant hirudin in mixed aqueous–organic solutions09/02/2019
- Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite in human serum09/01/2019
- Effects of linear and branched polyethylene glycol on PEGylation of recombinant hirudin: Reaction kinetics and in vitro and in vivo bioactivities08/30/2019
- Regular ArticlePEGylation kinetics of recombinant hirudin and its application for the production of PEGylated HV2 species08/29/2019
- Chemical modification of recombinant hirudin with palmitic acid in mixed aqueous-organic solutions08/28/2019


